Literature DB >> 21427401

Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity.

Timothy J Wilkin1, Mathew Bidwell Goetz, Robert Leduc, Gail Skowron, Zhaohui Su, Ellen S Chan, Jayyant Heera, Doug Chapman, John Spritzler, Jacqueline D Reeves, Roy M Gulick, Eoin Coakley.   

Abstract

The enhanced-sensitivity Trofile assay (TF-ES; Monogram Biosciences) was used to retest coreceptor tropism samples from 4 different cohorts of HIV-1-infected patients. Nine percent to 26% of patients with CCR5-tropic virus by the original Trofile assay had CXCR4-using virus by TF-ES. Lower CD4 cell counts were associated with CXCR4-using virus in all cohorts.
© The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21427401      PMCID： PMC3106234          DOI： 10.1093/cid/cir072

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

1.  Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism.

Authors:  Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.

Authors:  David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin Dejesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna Van Der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

3.  Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.

Authors:  Roy M Gulick; Zhaohui Su; Charles Flexner; Michael D Hughes; Paul R Skolnik; Timothy J Wilkin; Robert Gross; Amy Krambrink; Eoin Coakley; Wayne L Greaves; Andrew Zolopa; Richard Reichman; Catherine Godfrey; Martin Hirsch; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2007-06-05       Impact factor: 5.226

4.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

5.  Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Authors:  Zhaohui Su; Roy M Gulick; Amy Krambrink; Eoin Coakley; Michael D Hughes; Dong Han; Charles Flexner; Timothy J Wilkin; Paul R Skolnik; Wayne L Greaves; Daniel R Kuritzkes; Jacqueline D Reeves
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

6.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.

Authors:  Brandon F Keele; Elena E Giorgi; Jesus F Salazar-Gonzalez; Julie M Decker; Kimmy T Pham; Maria G Salazar; Chuanxi Sun; Truman Grayson; Shuyi Wang; Hui Li; Xiping Wei; Chunlai Jiang; Jennifer L Kirchherr; Feng Gao; Jeffery A Anderson; Li-Hua Ping; Ronald Swanstrom; Georgia D Tomaras; William A Blattner; Paul A Goepfert; J Michael Kilby; Michael S Saag; Eric L Delwart; Michael P Busch; Myron S Cohen; David C Montefiori; Barton F Haynes; Brian Gaschen; Gayathri S Athreya; Ha Y Lee; Natasha Wood; Cathal Seoighe; Alan S Perelson; Tanmoy Bhattacharya; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-19       Impact factor: 11.205

7.  A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

Authors:  Michael Saag; James Goodrich; Gerd Fätkenheuer; Bonaventura Clotet; Nathan Clumeck; John Sullivan; Mike Westby; Elna van der Ryst; Howard Mayer
Journal:  J Infect Dis       Date:  2009-06-01       Impact factor: 5.226

8.  Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects.

Authors:  Gail Skowron; John G Spritzler; Jodi Weidler; Gregory K Robbins; Victoria A Johnson; Ellen S Chan; David M Asmuth; Rajesh T Gandhi; Yolanda Lie; Michael Bates; Richard B Pollard
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731

9.  Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.

Authors:  Matthew Bidwell Goetz; Robert Leduc; Jay R Kostman; Ann M Labriola; Yolanda Lie; Jodi Weidler; Eoin Coakley; Michael Bates; Roberta Luskin-Hawk
Journal:  J Acquir Immune Defic Syndr       Date:  2009-03-01       Impact factor: 3.731
  9 in total
  23 in total

1.  Virological response after short-term CCR5 antagonist exposure in HIV-infected patients: frequency of subjects with virological response and associated factors.

Authors:  Ezequiel Ruiz-Mateos; Alejandro González-Serna; Miguel Genebat; Kawthar Machmach; Francesc Vidal; Angeles Muñoz-Fernández; Sara Ferrando-Martinez; Manuel Leal
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

2.  HIV-1 tropism testing and clinical management of CCR5 antagonists: Quebec review and recommendations.

Authors:  Cécile Tremblay; Isabelle Hardy; Richard Lalonde; Benoit Trottier; Irina Tsarevsky; Louis-Philippe Vézina; Michel Roger; Mark Wainberg; Jean-Guy Baril
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

Review 3.  CCR5 antagonism in HIV infection: current concepts and future opportunities.

Authors:  Timothy J Wilkin; Roy M Gulick
Journal:  Annu Rev Med       Date:  2011-10-27       Impact factor: 13.739

4.  Dual-mixed HIV-1 coreceptor tropism and HIV-associated neurocognitive deficits.

Authors:  Sheldon R Morris; Steven Paul Woods; Reena Deutsch; Susan J Little; Gabriel Wagner; Erin E Morgan; Robert K Heaton; Scott L Letendre; Igor Grant; Davey M Smith
Journal:  J Neurovirol       Date:  2013-10       Impact factor: 2.643

5.  A diagnostic HIV-1 tropism system based on sequence relatedness.

Authors:  Suzanne Edwards; Heinz Stucki; Joëlle Bader; Vincent Vidal; Rolf Kaiser; Manuel Battegay; Thomas Klimkait
Journal:  J Clin Microbiol       Date:  2014-12-10       Impact factor: 5.948

6.  Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc Switch collaborative study.

Authors:  Elise Tu; Luke C Swenson; Sally Land; Sarah Pett; Sean Emery; Kat Marks; Anthony D Kelleher; Steve Kaye; Rolf Kaiser; Eugene Schuelter; Richard Harrigan
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948

7.  Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects.

Authors:  Ron M Kagan; Erik P Johnson; Martin F Siaw; Ben Van Baelen; Richard Ogden; Jamie L Platt; Rick L Pesano; Eric Lefebvre
Journal:  AIDS Res Hum Retroviruses       Date:  2013-08-14       Impact factor: 2.205

8.  Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Authors:  Luke C Swenson; Celia K S Chui; Chanson J Brumme; Dennison Chan; Conan K Woods; Theresa Mo; Winnie Dong; Doug Chapman; Marilyn Lewis; James F Demarest; Ian James; Simon Portsmouth; James Goodrich; Jayvant Heera; Hernan Valdez; P Richard Harrigan
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

9.  A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients.

Authors:  Ron M Kagan; Erik P Johnson; Martin Siaw; Pinaki Biswas; Douglass S Chapman; Zhaohui Su; Jamie L Platt; Rick L Pesano
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

Review 10.  Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.

Authors:  Yi-Wei Tang; Chin-Yih Ou
Journal:  Emerg Microbes Infect       Date:  2012-08-22       Impact factor: 7.163
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.